The product, which is available in the 5mg and 10mg strengths, is indicated for the treatment of narcolepsy and attention deficit disorder with hyperactivity.
The company received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) in March 2014.
According to IMS data, the dextroamphetamine immediate release tablet market had US sales of about $41m as of April 2014.
The company operates a facility, totalling 112,000ft² of space, in Middlesex, New Jersey.
CorePharma is a subsidiary of Tower Holdings and it actively seeks partnerships, licensing and acquisition opportunities to complement and expand its product portfolio.